Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36,193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C. Shi Y, et al. Among authors: liu j, liu y, liu c, liu f. J Thorac Oncol. 2022 Nov;17(11):1297-1305. doi: 10.1016/j.jtho.2022.07.1143. Epub 2022 Aug 3. J Thorac Oncol. 2022. PMID: 35932953 Free article. Clinical Trial.
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y, Gu C; FURLONG investigators. Shi Y, et al. Among authors: liu j, liu y, liu c, liu f. Lancet Respir Med. 2022 Nov;10(11):1019-1028. doi: 10.1016/S2213-2600(22)00168-0. Epub 2022 Jun 2. Lancet Respir Med. 2022. PMID: 35662408 Clinical Trial.
Engineered Extracellular Vesicle-Delivered CRISPR/CasRx as a Novel RNA Editing Tool.
Li T, Zhang L, Lu T, Zhu T, Feng C, Gao N, Liu F, Yu J, Chen K, Zhong J, Tang Q, Zhang Q, Deng X, Ren J, Zeng J, Zhou H, Zhu J. Li T, et al. Among authors: liu f. Adv Sci (Weinh). 2023 Apr;10(10):e2206517. doi: 10.1002/advs.202206517. Epub 2023 Feb 2. Adv Sci (Weinh). 2023. PMID: 36727818 Free PMC article.
RNA analysis of patients with benign and malignant pulmonary nodules.
Liu G, Liu Q, He Y, Wei L, Liang D, Xie S, Zhang N, Geng N, Zhang L, Huang Y, Liu F. Liu G, et al. Among authors: liu f. Oncol Lett. 2025 Jan 7;29(3):132. doi: 10.3892/ol.2025.14878. eCollection 2025 Mar. Oncol Lett. 2025. PMID: 39822942 Free PMC article.
36,193 results
You have reached the last available page of results. Please see the User Guide for more information.